2024
External validation of the SI2NCAL2C score for outcomes following cerebral venous thrombosis
Klein P, Shu L, Lindgren E, de Winter M, Siegler J, Simpkins A, Omran S, Heldner M, de Havenon A, Abdalkader M, Al Kasab S, Stretz C, Wu T, Wilson D, Asad S, Almallouhi E, Frontera J, Kuohn L, Rothstein A, Bakradze E, Henninger N, Zubair A, Sharma R, Kerrigan D, Aziz Y, Mistry E, van Kammen M, Tatlisumak T, Krzywicka K, Aguiar de Sousa D, Jood K, Field T, Yaghi S, Coutinho J, Nguyen T. External validation of the SI2NCAL2C score for outcomes following cerebral venous thrombosis. Journal Of Stroke And Cerebrovascular Diseases 2024, 33: 107720. PMID: 38614162, DOI: 10.1016/j.jstrokecerebrovasdis.2024.107720.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisArea under the receiver operating characteristic curvePoor outcomeVenous thrombosisCentral nervous system infectionInternational retrospective studyNervous system infectionExternal validation cohortFocal neurological deficitsReceiver operating characteristic curvePoor outcome dataLevels of hemoglobinLack of follow-upPoorer outcome scoresConsecutive patientsClinical presentationRetrospective studyValidation cohortIntracerebral hemorrhageNeurological deficitsFollow-upOutcome scoresSystemic infectionLevels of glucoseInternational cohort
2022
Characteristics and outcomes of postpartum cerebral venous sinus thrombosis: A subgroup analysis of the ACTION-CVT study
Fang T, Shu L, Elnazeir M, Zubair AS, Al Kasab S, Antonenko K, Heldner MR, Yaghi S, Henninger N, collaborators A. Characteristics and outcomes of postpartum cerebral venous sinus thrombosis: A subgroup analysis of the ACTION-CVT study. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106865. PMID: 36332527, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106865.Peer-Reviewed Original ResearchConceptsCerebral venous sinus thrombosisVenous sinus thrombosisSinus thrombosisMajor hemorrhageNon-postpartum womenVenous thrombosis studyTreatment-related complicationsVenous thromboembolism recurrenceOne-year outcomesOne-year riskLong-term outcomesNon-pregnant femalesCause deathThromboembolism recurrenceVTE recurrenceEarly complicationsDischarge dispositionRankin ScaleSecondary outcomesVenous infarctionPostpartum statusPrimary outcomeFunctional disabilityIntracranial hemorrhagePotential confoundersPredictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis
Shu L, Bakradze E, Omran SS, Giles J, Amar J, Henninger N, Elnazeir M, Liberman A, Moncrieffe K, Rotblat J, Sharma R, Cheng Y, Zubair AS, Simpkins A, Li G, Kung J, Perez D, Heldner MR, Scutelnic A, von Martial R, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio HJ, Frontera JA, Kuohn L, Agarwal S, Stretz C, Kala N, ElJamal S, Chang A, Cutting S, Indraswari F, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad D, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Grory BM, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler J, Kamen S, Yu S, Guerrero CL, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind D, Furie K, Yaghi S. Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis. Neurology 2022, 99: e2368-e2377. PMID: 36123126, PMCID: PMC9687409, DOI: 10.1212/wnl.0000000000201122.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, AntiphospholipidFemaleHumansIntracranial ThrombosisMaleMiddle AgedNeoplasm Recurrence, LocalPregnancyRisk FactorsVenous ThromboembolismVenous ThrombosisConceptsCerebral venous thrombosisRecurrent venous thrombosisHistory of VTEVenous thrombosisVenous thromboembolismAntiphospholipid antibodiesBlack raceDiagnosis of CVTPositive antiphospholipid antibodiesRecurrent venous thrombosesAntiphospholipid antibody syndromeRecurrent venous thromboembolismCox regression analysisRisk of recurrenceMulticenter international studyAntibody syndromeOral anticoagulationVenous thrombosesConsecutive patientsRare causeMean ageTreatment strategiesThrombosisPatientsSecondary analysisDirect Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
Yaghi S, Shu L, Bakradze E, Omran S, Giles JA, Amar JY, Henninger N, Elnazeir M, Liberman AL, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair AS, Simpkins AN, Li GT, Kung JC, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, Jamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad SD, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler JE, Kamen S, Yu S, Guerrero C, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind DS, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022, 53: 728-738. PMID: 35143325, DOI: 10.1161/strokeaha.121.037541.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVenous thrombosisRecurrent venous thrombosisMajor hemorrhageInclusion criteriaDirect Oral Anticoagulants Versus WarfarinMulticenter international retrospective studyInverse probabilityInternational retrospective studySystemic venous thrombosisFavorable safety profileCox regression modelMulticenter international studyAnalysis inclusion criteriaBaseline imaging dataCVT patientsOral anticoagulationComplete recanalizationDOAC treatmentOral anticoagulantsRadiological outcomesRadiographic outcomesVersus WarfarinWarfarin treatment